- Report
- December 2025
- 200 Pages
Global
From €7132EUR$7,950USD£6,097GBP
- Report
- August 2025
- 187 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- February 2024
- 180 Pages
Global
From €4457EUR$4,969USD£3,811GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1794EUR$2,000USD£1,534GBP
- Report
- May 2024
- 136 Pages
Global
From €2690EUR$2,999USD£2,300GBP
€3587EUR$3,999USD£3,067GBP
- Report
- August 2024
- 104 Pages
Global
From €3500EUR$4,180USD£3,097GBP
The GABA Receptor Agonist market is a subset of the Central Nervous System Drugs market. GABA Receptor Agonists are drugs that activate the GABA receptor, a type of neurotransmitter receptor found in the brain. These drugs are used to treat a variety of neurological disorders, including anxiety, insomnia, and epilepsy. GABA Receptor Agonists are typically administered orally, intravenously, or intramuscularly.
The GABA Receptor Agonist market is highly competitive, with a number of large pharmaceutical companies vying for market share. Companies in this market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Additionally, there are a number of smaller companies that specialize in the development and manufacture of GABA Receptor Agonists. Show Less Read more
